Singlera Genomics, Inc. is thrilled to announce a significant milestone in our journey toward revolutionizing genetic and genomic analysis. Our pioneering efforts have been officially recognized with the awarding of Patent Number 11965157. This patent covers the innovative compositions and methods for constructing polynucleotide libraries and/or polynucleotide sequencing, including related kits and devices, which are integral to our Titan and mTitan Technology and products.
This patented technology marks a significant leap forward by enhancing the ligation efficiency and conversion rate during sequencing processes. It represents a major advancement in genetic research and diagnostics. Specifically, our technology offers targeted solutions for analyzing polynucleotide fragments, including circulating tumor DNA and other circulating polynucleotide fragments. This opens new pathways for the detection and understanding of various diseases at the molecular level, providing a foundation for more effective treatments and diagnostics.
This achievement underscores the dedication, creativity, and hard work of our team at Singlera Genomics, Inc. We extend our heartfelt gratitude and congratulations to the inventors, Jeffrey Gole, Athurva Gore, and Rui Liu, whose contributions have been instrumental in reaching this milestone.
Our mission to advance the frontiers of genomics and personalized medicine is further invigorated by this accomplishment. We are eager to leverage our patented technologies to support researchers, clinicians, and patients worldwide, offering new insights and possibilities in genomic analysis.
Stay tuned for further updates and insights on how our patented technologies are paving the way for future breakthroughs in genomic analysis.
Link: https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11965157
